[{"orgOrder":0,"company":"Sichuan University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Sichuan University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan University \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Sichuan University \/ AstraZeneca"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Famous Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Famous Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Centre, Singapore","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Centre, Singapore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Centre, Singapore \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Centre, Singapore \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"National Cancer Center, Korea","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Center, Korea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Center, Korea \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Center, Korea \/ AstraZeneca"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Asan Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"China-Japan Friendship Hospital | Peking University Cancer Hospital & Institute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chinese PLA General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ China-Japan Friendship Hospital | Peking University Cancer Hospital & Institute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chinese PLA General Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Qilu Pharmaceutical \/ China-Japan Friendship Hospital | Peking University Cancer Hospital & Institute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chinese PLA General Hospital"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"AIO-Studien-gGmbH \/ AstraZeneca"},{"orgOrder":0,"company":"Intergroupe Francophone de Cancerologie Thoracique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Intergroupe Francophone de Cancerologie Thoracique","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed"},{"orgOrder":0,"company":"Spanish Lung Cancer Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spanish Lung Cancer Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Lung Cancer Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spanish Lung Cancer Group \/ Undisclosed"},{"orgOrder":0,"company":"Papworth Hospital NHS Foundation Trust","sponsor":"AstraZeneca | Noble Organisation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Papworth Hospital NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Papworth Hospital NHS Foundation Trust \/ AstraZeneca | Noble Organisation","highestDevelopmentStatusID":"8","companyTruncated":"Papworth Hospital NHS Foundation Trust \/ AstraZeneca | Noble Organisation"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Quintiles Inc","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Quintiles Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ AstraZeneca"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Gustave Roussy","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Gustave Roussy"}]
Find Clinical Drug Pipeline Developments & Deals for Irressat
Sponsor :
China-Japan Friendship Hospital | Peking University Cancer Hospital & Institute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chinese PLA General Hospital
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Neoplasms.
Sponsor :
China-Japan Friendship Hospital | Peking University Cancer Hospital & Institute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chinese PLA General Hospital
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Details :
Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Reset All
